Cancer and myositis: Who, when, and how to screen.
Cancer
Dermatomyositis
Idiopathic inflammatory myopathies
Malignancy
Polymyositis
Journal
Best practice & research. Clinical rheumatology
ISSN: 1532-1770
Titre abrégé: Best Pract Res Clin Rheumatol
Pays: Netherlands
ID NLM: 101121149
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
pubmed:
16
8
2022
medline:
28
9
2022
entrez:
15
8
2022
Statut:
ppublish
Résumé
Cancer screening in idiopathic inflammatory myopathies (IIMs) is essential because an increased risk of cancer in IIMs has been well demonstrated. However, a consensus regarding cancer screening approaches is lacking. Therefore, the approach presented in this review reflects available evidence and our clinical experiences. Patients with IIMs should be evaluated for 3 distinct types of risk categories: (a) clinical with their history, physical examination, and laboratory parameters; (b) based on IIMs subtypes; and (c) based on serology - myositis specific and associated autoantibodies. Further, according to these characteristics, patients should be classified as low risk, moderate risk, and high risk for cancer. In our approach, all patients with IIM within 3 years of disease onset should undertake cancer screening according to their risk stratification. First, irrespective of risk, all patients should undergo age and gender-appropriate screening as per local guidelines. Patients at low-risk stratification should undertake basic cancer screening with routine blood counts, labs, and imaging; at moderate-risk stratification, patients should undertake enhanced cancer screening including CT chest; and at high-risk stratification, patients should undertake comprehensive cancer screening including PET/CT at baseline. Consensus guidelines among all major stakeholders, including rheumatologists, neurologists, dermatologists, and oncologists representing different parts of the world, establishing uniform cancer screening approaches in patients with IIM, are the need of the hour.
Identifiants
pubmed: 35970749
pii: S1521-6942(22)00030-4
doi: 10.1016/j.berh.2022.101771
pii:
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101771Informations de copyright
Copyright © 2022. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no conflicts of interest regarding the submitted manuscript. Outside of the submitted manuscript, SK has received congress travel, accommodation, and participation fee support (12th Anatolian Rheumatology Days) from Abbvie (payments were made to congress).